ATE429916T1 - Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme - Google Patents

Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme

Info

Publication number
ATE429916T1
ATE429916T1 AT02783922T AT02783922T ATE429916T1 AT E429916 T1 ATE429916 T1 AT E429916T1 AT 02783922 T AT02783922 T AT 02783922T AT 02783922 T AT02783922 T AT 02783922T AT E429916 T1 ATE429916 T1 AT E429916T1
Authority
AT
Austria
Prior art keywords
food consumption
treating obesity
sulfonamide derivatives
reducing food
treatment
Prior art date
Application number
AT02783922T
Other languages
English (en)
Inventor
Patrizia Caldirola
Original Assignee
Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0103767A external-priority patent/SE0103767D0/xx
Application filed by Biovitrum Ab Publ filed Critical Biovitrum Ab Publ
Application granted granted Critical
Publication of ATE429916T1 publication Critical patent/ATE429916T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Quinoline Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT02783922T 2001-11-09 2002-11-06 Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme ATE429916T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0103767A SE0103767D0 (sv) 2001-11-09 2001-11-09 New use
US35689002P 2002-02-13 2002-02-13
PCT/SE2002/002019 WO2003039547A1 (en) 2001-11-09 2002-11-06 Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake

Publications (1)

Publication Number Publication Date
ATE429916T1 true ATE429916T1 (de) 2009-05-15

Family

ID=26655592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02783922T ATE429916T1 (de) 2001-11-09 2002-11-06 Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme

Country Status (6)

Country Link
US (1) US20030166663A1 (de)
EP (1) EP1450806B1 (de)
JP (1) JP2005511594A (de)
AT (1) ATE429916T1 (de)
DE (1) DE60232173D1 (de)
WO (1) WO2003039547A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1897881A3 (de) * 2002-06-20 2009-03-18 Biovitrum AB (publ) Zur Behandlung von Obesitas, Typ II-Diabetes und ZNS-Erkrankungen geeignete Verbindungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
AU2005299771A1 (en) * 2004-10-21 2006-05-04 High Point Pharmaceuticals, Llc Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
EP1910321A4 (de) * 2005-07-05 2010-09-01 Astrazeneca Ab Neue verbindungen, verfahren zu ihrer herstellung, zwischenprodukte, pharmazeutische zusammensetzungen und ihre verwendung bei der behandlung von durch 5-ht6-vermittelten erkrankungen wie alzheimer-krankheit, kognitiven erkrankungen, mit schizophrenie assoziierten kognitiven störungen, obesitas und parkinson-krankheit
EP1902041A4 (de) * 2005-07-05 2010-03-17 Astrazeneca Ab Neue verbindungen, verfahren zu ihrer herstellung, zwischenprodukte, pharmazeutische zusammensetzungen und ihre verwendung bei der behandlung von durch 5-ht6-vermittelten erkrankungen wie alzheimer-krankheit, kognitiven erkrankungen, mit schizophrenie assoziierten kognitiven störungen, obesitas und parkinson-krankheit
JP4434182B2 (ja) 2006-07-25 2010-03-17 セイコーエプソン株式会社 眼鏡レンズの設計方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP4424697A3 (de) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultrareine agonisten der guanylatcyclase c, verfahren zur herstellung und verwendung davon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6391894A (en) 1993-03-16 1994-10-11 Pfizer Inc. Naphthalene derivatives
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
WO1999044609A1 (en) * 1998-03-03 1999-09-10 Merck & Co., Inc. FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS
TWI222450B (en) * 1999-07-28 2004-10-21 Upjohn Co Oxazinocarbazoles for the treatment of CNS diseases
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
US6399617B1 (en) * 2000-07-21 2002-06-04 Biovitrum Ab Use

Also Published As

Publication number Publication date
WO2003039547A1 (en) 2003-05-15
DE60232173D1 (de) 2009-06-10
JP2005511594A (ja) 2005-04-28
US20030166663A1 (en) 2003-09-04
EP1450806B1 (de) 2009-04-29
EP1450806A1 (de) 2004-09-01

Similar Documents

Publication Publication Date Title
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
ATE353646T1 (de) Verwendung von indol- und indolin-derivaten bei der behandlung von adipositas oder zur reduzierung der nahrungsaufnahme
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA200802329A1 (ru) Производные триазола ii
DE50310516D1 (de) Fredericamycin-derivate
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
MXPA05011203A (es) Fenacil-2-hidroxi-3-diaminoalcanos.
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
DE602006010442D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
DK1558620T3 (da) Rutheniumkomplekser med anticancervirkning
ATE267597T1 (de) Verwendung von polycyclischen 2-amino-thiazol systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
DE50007381D1 (de) Verwendung von polyzyklischen thiazol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
SE0002739D0 (sv) New use
MXPA05007715A (es) Derivados de carboxamida y uso de los mismos como inhibidores del factor xa.
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
DE60310975D1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties